Your session is about to expire
← Back to Search
Needling Device
Straberi Epistamp Needling Treatment for Postinflammatory Hyperpigmentation (EPH Trial)
N/A
Waitlist Available
Led By Maurice E Wright, MD
Research Sponsored by Universal Skincare Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
Summary
This trialtests a new device to reduce the dark spots caused by acne.
Eligible Conditions
- Postinflammatory Hyperpigmentation
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
The Global Aesthetic Improvement Scale (GAIS)
Secondary outcome measures
Overall Skin improvement assessed by Derma Scan
Overall Skin improvement assessed by Post Acne Hyperpigmentation Index (PAHPI)
Photographs
+1 moreTrial Design
2Treatment groups
Experimental Treatment
Group I: Straberi Epistamp Needling TreatmentExperimental Treatment1 Intervention
Non-Randomized treatment for patients with Postinflammatory Hyperpigmentation (PIH) using the Straberi Epistamp needling.
Group II: No TreatmentExperimental Treatment1 Intervention
Non-Randomized patients with Postinflammatory Hyperpigmentation (PIH)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Straberi Epistamp
2022
N/A
~30
Find a Location
Who is running the clinical trial?
Universal Skincare InstituteLead Sponsor
2 Previous Clinical Trials
55 Total Patients Enrolled
Lavish BeautyUNKNOWN
2 Previous Clinical Trials
55 Total Patients Enrolled
Maurice E Wright, MDPrincipal InvestigatorColumbia University
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger